Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073515 · ClinicalTrials.gov registry record · Phase 2
Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices
A Phase 2 study, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT00073515: Completed Phase 2 study, sponsored by ARCA Biopharma.
NCT00073515 is a Phase 2 study that has completed, run by ARCA Biopharma. The registered enrollment target is 115 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073515, a Phase 2 study, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.
Interventions
- DRUG Alfimeprase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Phase | Phase 2 |
What the finished NCT00073515 record still lists
NCT00073515 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 1 intervention - of which Alfimeprase is the first listed.
NCT00073515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00073515 about?
NCT00073515 is a clinical study titled "Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices". This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.
What is the current status of trial NCT00073515?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants.
What interventions are being tested in trial NCT00073515?
The interventions under investigation include: Alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00073515?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00073515's enrollment target sits among peer trials
115 626th of 2000 higher than 1,374 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study